Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 9Terminated 4Unknown 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 36Plasma cell 24Other hematologic neoplasm 7Myeloid 3Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1CNS 1

Conditions

Colorectal Neoplasms 2Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 283Capecitabine 217Fluorouracil 210Irinotecan 145Leucovorin 136Gemcitabine 121S 1 (combination) 110apatinib 108Cisplatin 99Radiotherapy 97Bevacizumab 97Drug Therapy 94Paclitaxel 93camrelizumab 88sintilimab 77Cetuximab 74lenvatinib 60Neoadjuvant Therapy 59tislelizumab 54Surgical Procedures, Operative 54Sorafenib 53Folfox protocol 52Docetaxel 51toripalimab 50130-nm albumin-bound paclitaxel 45Laparoscopy 41HMPL-013 40XELOX 38Albumin-Bound Paclitaxel 36regorafenib 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Lenalidomide × Gastrointestinal × Clear all
NCT04326296 2020-05-15

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Henan Cancer Hospital

Phase 1 Unknown
33 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01166035 2010-07-20

TEXO

Medical University Innsbruck

Phase 1/2 Unknown
20 enrolled
GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡